New York, NY, United States – AUGUST 31, 2026 – With years of experience in the pharmaceutical and life science sectors, CD Bioparticles is pleased to announce its Homogeneous Luminescence Assay Development services, to support researchers with sensitive, efficient, and high-throughput detection of biomarkers, cytokines, and other biological targets. The new service enables scientists to accelerate assay development while minimizing workflow complexity for drug discovery, immunology, and translational research applications.
Unlike electrochemiluminescence, direct chemiluminescence or enzyme-catalyzed chemiluminescence, homogeneous luminescence technology uses two types of markers: a luminescent material and a photosensitizer. The photosensitizer is distributed on the surface of donor polystyrene microspheres, while the chemiluminescent dye is distributed on the surface of acceptor polystyrene microspheres. These two types of microsphere interact via antigen-antibody binding, enabling the transfer of high-energy reactive oxygen species and triggering the light-induced chemiluminescence process. This makes “non-separation” homogeneous immunoassays possible, characterized by high precision and rapid detection.
Based on this assay platform, CD Bioparticles has developed dozens of clinically relevant tests, including those for infectious disease biomarkers, serum tumour markers, thyroid function-related hormones, reproductive hormones and cardiac emergency markers. CD Bioparticles provides comprehensive solutions ranging from homogeneous assay raw materials to technical development and large-scale production. Leveraging extensive experience in innovative R&D and mass production, CD Bioparticles assists clients in developing homogeneous, chemiluminescence-based products, thereby reducing development costs and shortening R&D cycles.
CD Bioparticles’ services cover every stage, from custom conjugation to optimizing complete assay systems. This includes evaluating and screening antibodies and antigens, selecting donors and acceptors for custom antigen/antibody conjugation, optimizing conjugation conditions, optimizing reaction systems (including sample volume, donor and acceptor concentrations, and buffer systems), and validating assays. These homogeneous chemiluminescent assays can be used for biomarker detection for in vitro diagnostics (IVD), detecting protein-protein interactions, and identifying post-translational modifications.
CD Bioparticles’ homogeneous chemiluminescent immunoassay development services are tailored to the unique needs of each research project. Its team of experts provides end-to-end support, including assay design, optimization, and post-market assistance. The company offers scalable, cost-effective solutions, with production processes capable of meeting a wide range of throughput requirements—from small-scale R&D needs to large-scale commercial production.
Additionally, CD Bioparticles provides high-quality donors and receptors with diverse surface characteristics and consistent quality to accommodate various conjugation methods. The company possesses extensive experience in assay design, raw material selection, conjugation and buffer system optimization, and assay validation.
CD Bioparticles offers custom services to help help researchers and diagnostic manufacturers develop homogeneous luminescence assays. To learn more about CD Bioparticles’ assay development services or to request a project consultation, please visit CD Bioparticles official website at: https://www.cd-bioparticles.com/services/homogeneous-luminescence-assay-development.html.
About CD Bioparticles
CD Bioparticles is a leading manufacturer and supplier of various nanoparticles, microparticles, and coatings for R&D as well as commercialization across different application areas, including in vitro diagnostics, biochemistry, cellular analysis, cell separation, and immunoassay. The company also offers various custom services, including chemical surface-functionalization, fluorescent modification, antibody immobilization, as well as nucleic acid and oligo conjugation to meet client specifications.
Media ContactCompany Name: CD BioparticlesContact Person: Richard J. GrayEmail: Send EmailCity: ShirleyState: New YorkCountry: United StatesWebsite: https://www.cd-bioparticles.com/
